Dermis Density, Trans Epidermal Water Loss (TEWL), Skin Hydration, Wrinkles, Dermis Thickness
Conditions
Brief summary
Placebo controlled double-blind multi-dose comparative study of the effects of coenzyme Q10 and collagen formulation with improved water-solubility in healthy adults. One group (test group) will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg) and the other (placebo group) placebo syrup without those active ingredients. Participants will test continuous administration of placebo or investigational product for 12 weeks in order to demonstrate and assess multiple-dose effects on skin condition and signs of skin aging.
Interventions
DIETARY_SUPPLEMENTPlacebo syrup
Placebo group will receive placebo syrup without active ingredients. (daily dose 10 mL: fish collagen: 0 mg, water soluble CoQ10 (Q10Vital®): 0 mg, vitamin C: 0 mg, vitamin A: 0 μg, biotin: 0 μg); continous administration of placebo product for 12 weeks.
DIETARY_SUPPLEMENTTest syrup containing CoQ10 and collagen
Test group will receive investigational product - test syrup (daily dose 10 mL: fish collagen: 4000 mg, water soluble CoQ10 (Q10Vital®): 50 mg, vitamin C: 80 mg, vitamin A: 920 μg, biotin: 150 μg); continuous administration of investigational product for 12 weeks.
Sponsors
European Regional Development Fund
Valens Int. d.o.o., Slovenija
Ministry of Education, Science and Sport, Republic of Slovenia
VIST - Faculty of Applied Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Caucasian female volunteers aged between 40 and 65 years at the time of the signature of Informed consent form (ICF), * Signed Informed consent form (ICF), * Fitzpatrick skin phototypes II and III, * Signs of skin aging, * In good health condition, * Willingness to avoid a consumption of any food supplements containing CoQ10 and other antioxidants, collagen or vitamins during the study, * Willingness to follow all study procedures and keeping a diary during the study (to follow their compliance and palatability).
Exclusion criteria
* Pregnancy or breastfeeding, * Known or suspected allergy to any ingredient of the tested products, * Changes in dietary habits and dietary supplementation in last three months prior to inclusion, * Regular use of food supplements containing CoQ10 or other antioxidants, collagen or other protein-based food supplements, vitamin A, vitamin E or biotin in last three months prior to inclusion, * Veganism, * Changes in cosmetic facial and body care routine in last month prior to inclusion, * Diagnosed and uncontrolled/untreated/unregulated disease, * Any clinically significant history of serious metabolic disease, digestive tract disease, liver disease, kidney disease, haematological disease, * Acute skin diseases, * Skin pigmentation disorders, * Increased cholesterol and use of cholesterol lowering drugs (statins), * Anticipated sunbathing or solarium visits before or during the study, * Invasive rejuvenation treatments (e.g. needle rollers, needle mesotherapy, deep/medium-deep chemical peels etc.) in last 6 months prior to study entry, * Non-invasive rejuvenation treatments (e.g. radiofrequency, electrotherapy, ultrasound therapy) in last 2 months prior to study entry, * Mental incapacity that precludes adequate understanding or cooperation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Influence of investigational product in relation to placebo product on dermis density assessed through dermis intensity measurement | 12 weeks | Significant change of dermis density from baseline in test group, in comparison to placebo group after 12 weeks of dietary supplementation with study product is expected. Dermis density will be assessed through ultrasonographic dermis intensity measurement. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Influence of the investigational product in relation to placebo product on skin elasticity assessed through measurements of viscoelasticity | 12 weeks | For assessments of skin viscoelasticity measurements will be performed. Significant change of skin viscoeasticity from baseline in test group, in comparison to placebo group after 12 weeks of dietary supplementation with study product is expected. |
| Influence of the investigational product in relation to placebo product on skin hydration | 12 weeks | Assessment of the effects of the investigational product on skin hydration after 12 weeks of dietary supplementation. Skin hydration measurements will be performed using conductance principle. |
| Influence of the investigational product in relation to placebo product on TEWL | 12 weeks | Assessment of the effects of investigational product on transepidermal water loss after 12 weeks of dietary supplementation. TEWL measurements will be performed using open chambre principle. |
| Influence of investigational product in relation to placebo product on dermis thickness | 12 weeks | Significant change of dermis thickness from baseline in test group, in comparison to placebo group after 12 weeks of dietary supplementation with study product is expected. Dermis density will be assessed using ultrasonography. |
| Influence of investigational product in relation to placebo product on wrinkles will be assessed using wrinkle area fraction measurements | 12 weeks | Assessment of the effects of investigational product on facial wrinkles after 12 weeks of dietary supplementation will be done using wrinkle area fraction measurements. |
Countries
Slovenia
Outcome results
None listed